xenon
Phase 3- Indications
- Post Cardiac Arrest Syndrome
Company intelligence / Profile preview
Invero Pharma
Montville, New Jersey, USAinveropharma.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Invero Pharma’s lead program uses inhaled xenon gas via a proprietary device to reduce brain damage after acute neurologic injury. Positive Phase II results showed reduced brain tissue damage and directionally better survival outcomes. The company holds orphan drug status and fast-track designation from FDA/EMA and plans a pivotal Phase III trial in out-of-hospital cardiac arrest patients.
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Small molecule gas (xenon)drug/device combination
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Rheos Medical Corporation collaboration to improve survival post-cardiac arrest (2024)
Beyond the preview
Go deeper on Invero Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Invero Pharma.